Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report

Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report

ABSTRACT: Managing pediatric Crohn's disease (PCD) presents challenges due to severe complications and higher biologic therapy needs. Transitioning from anti–tumor necrosis factor agents to off-label therapies adds complexity. Although upadacitinib has demonstrated efficacy and tolerability in...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan Liu, MD, XiaoMei Song, MD, LingYa Xiang, MD, Wei Tan, MD, Min Zou, MD, Hong Guo, MD
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Current Therapeutic Research
Subjects:
ataxia telangiectasia mutated
case report
child
refractory Crohn's disease
upadacitinib
Online Access:http://www.sciencedirect.com/science/article/pii/S0011393X24000262
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT: Managing pediatric Crohn's disease (PCD) presents challenges due to severe complications and higher biologic therapy needs. Transitioning from anti–tumor necrosis factor agents to off-label therapies adds complexity. Although upadacitinib has demonstrated efficacy and tolerability in adult inflammatory bowel disease and pediatric atopic dermatitis, there are limited data for its application in PCD. This case report delineates successful remission with upadacitinib in a child with CD refractory to infliximab, ustekinumab, adalimumab, thalidomide, and prednisone. Notably, the patient carried an ataxia telangiectasia mutated (ATM) gene mutation. These findings provide valuable evidence for PCD management and highlight the potential benefits of upadacitinib in this population.
ISSN:0011-393X

Similar Items